Lung cancer kills 2 million people a year — and many patients only find out about the cancer when it’s already spread throughout their body. For these millions of people, the stakes have never been higher. And that’s exactly why we’re learning to outsmart lung cancer through precision medicine.
There are many different types of lung cancer, some driven by certain mutations that can be directly targeted. We’re developing new approaches that not only target what’s driving the cancer — but simultaneously target how the cancer tries to escape that kind of approach. This dual targeting is a completely new tactic, one we’re leading at J&J. And not only are we attacking cancer on two fronts — we’re leveraging the body’s own immune cells, like monocytes and macrophages, to help kill the cancer too.
We know the best chance to help patients is to use your best treatment first. Smartly designed medicines can outsmart the cancer, avoid the need for chemotherapy — and give patients their best first chance. For new hope. Better outcomes. And a brighter future.